Overactive bladder/enuresis:
Indications for: ENABLEX
Overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.
Adult Dosage:
Swallow whole with liquid. Initially 7.5mg once daily; may increase to 15mg once daily after 2 weeks. Moderate hepatic impairment (Child-Pugh B), concomitant potent CYP3A4 inhibitors: max 7.5mg once daily.
Children Dosage:
Not established.
ENABLEX Contraindications:
Patients with or at risk for: urinary or gastric retention, uncontrolled narrow-angle glaucoma.
ENABLEX Warnings/Precautions:
Severe hepatic impairment: not recommended. Bladder outflow obstruction. GI obstruction. Severe constipation. Ulcerative colitis. Myasthenia gravis. Controlled narrow-angle glaucoma. Monitor for CNS effects esp. after initiation or dose increases; consider reducing dose or discontinue if occurs. High environmental temperatures. Pregnancy. Nursing mothers.
ENABLEX Classification:
Muscarinic antagonist.
ENABLEX Interactions:
Potentiated by potent CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin, nefazadone); see Adult. May potentiate CYP2D6 substrates with narrow therapeutic indexes (eg, flecainide, thioridazine, TCAs). Additive anticholinergic effects with other anticholinergics.
Adverse Reactions:
Constipation, dry mouth, headache, dyspepsia, nausea, UTI, accidental injury, flu symptoms; angioedema (discontinue if occurs), CNS effects (eg, confusion, hallucination, somnolence).
Drug Elimination:
Renal (60%), fecal (40%). Half-life: 13–19 hours.
Generic Drug Availability:
YES
How Supplied:
Tabs—30, 90
